No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.
No article has been written about this topic yet.
Be the first one to add some text.
Loading AI-assisted edit mode...
Timeline
May 14, 2020
Boehringer Ingelheim acquires Northern Biologics' Preclinical Cancer Antibody Pipeline.
People
Name
Role
LinkedIn
Amr Youssef
Employee
Aaron Graham
Employee
Aashir Awan
Employee
Abbas Shivji
Employee
abdellatif ziane
Employee
Aditya Singh
Employee
Adrian van Alphen
Employee
Adriana Oreskovic
Employee
Agustina Yornet
Employee
Aisling Glennie
Employee
Alan Davis
Employee
Alan Wong
Employee
Albert Lens
Employee
Alberto Delmoral
Employee
Alceu Rodrigues de Freitas Junior
Employee
Alejandro Medici
Employee
Alejandro Piris
Employee
Alex Lincoln-Dodgson
Employee
Alex Pavlenko
Employee
Alexander Dross
Employee
Alicia Alonso- Boyanowski M.Ed
Employee
Alison Chiaramonte
Employee
Alison Fay
Employee
Ana Serafimovic
Employee
Andika Tyastono
Employee
Page 1 of 16
...
Further reading
Title
Author
Link
Type
Date
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
News
Title
Author
Date
Publisher
Description
Press Trust of India
July 31, 2020
@bsindia
Boehringer Ingelheim plans to bring innovative products catering mainly to pets and poultry segment in India, as it expects these verticals to grow in a robust manner over the next few years
Amirah Al Idrus
June 9, 2020
FierceBiotech
The COVID-19 pandemic has thrown a curve ball at the global economy, and the biopharma industry is no exception. Companies are scrambling to develop tests, treatments and vaccines for the disease, while making sure not to neglect their pipelines. We caught up with Ioannis Sapountzis, Boehringer Ingelheim's global head of business development and licensing, to see how the German pharma is handling this.
BioSpace
June 8, 2020
BioSpace
Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to better understand biology and disease-relevant processes is the use of well-characterized small chemical modulators of protein function. The new EUbOPEN consortium aims
Ben Adams
May 15, 2020
FierceBiotech
Boehringer Ingelheim is boosting its early-stage bets while also inking a new deal to work on a therapy against a leading cause of blindness.
May 14, 2020
BioSpace
Boehringer Ingelheim Acquires Northern Biologics' Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio - read this article along with other careers information, tips and advice on BioSpace
May 13, 2020
BioSpace
Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy, a Leading Cause of Blindness Worldwide - read this article along with other careers information, tips and advice on BioSpace
April 14, 2020
WebWire
For the fifth year, Boehringer Ingelheim sponsors the European PRRS Research Award to support applied research for improved control of the PRRS swine disease (Porcine Reproductive and Respiratory Syndrome). Research proposals for the 2020 European PRRS Research Award can be submitted until 1 July 2020. Boehringer Ingelheim will provide three grants of 25,000 euros each to fund research proposals that will generate new and relevant data to better understand this devastating and costly disea...
Sohini Das
March 1, 2020
@bsindia
Boehringer has expanded its field force to 570 representatives to boost their diabetes medicine sales that contributes nearly 75 per cent of the companys turnover
June 4, 2019
WebWire
, , , , • New digital disease management program "Tiba Yako" breaks access and awareness barriers in hypertension and diabetes care, , • The mobile-based technology allows patients to monitor their blood pressure and blood glucose levels at home, digitally sending the results to their doctor , , • Tiba Yako is an integrated disease service model that will offer benefits to patients, healthcare providers and payers alike , , • There is an unmet need for efficient affordable and widely accessible ca...
May 16, 2019
WebWire
Boehringer Ingelheim uses digital technologies along the entire value chain to discover the medications and healthcare solutions of the future. Collaboration with start-ups and other drivers of innovation is playing an increasingly important role, so Boehringer Ingelheim, a family-owned company, is complementing its internal expertise specifically by cooperating with external parties for research and development, production, and patient care. More than 150 cooperative projects are ongoing...
Research and Markets
Invalid Date
www.prnewswire.com:443
DUBLIN, Feb. 12, 2019 /PRNewswire/ -- The "Global Equine Healthcare Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key...
References
Is a
Company attributes
Location
Company status
Active
B2X
Subsidiary
Other attributes
Country
Categories
Related Topics
Contributors
- 1
Baye Maniago
Passionate about disruptive technology, continuous learning, and personal development - 2
Henry Ogolla
Passionate about reading and writing. - 3
Jude Gomila
Founder and CEO of Golden, Entrepreneur. Investor in 200+ companies. Cantabrigian (Gonville and Caius). Interested in the Universe. - 4
Dawson Sewell
Seeking to explain science and technology through simple writing. - 5
Carla Faraguna
Golden People and Operations.